Drug Trial Radar · NCT00384189
A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma
Last checked: Nov 19, 2026Latest source record: Feb 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,080
Actual
Start
Sep 2006
Primary completion
Aug 2007
Study completion Aug 2008
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Nycomed GmbH
- First posted
- Oct 5, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the efficacy of inhaled ciclesonide at three different dose levels compared with placebo with respect to pulmonary function, asthma symptoms, and use of rescue medication in children aged 6-11 years with asthma. Treatment medication will be administered as follows: ciclesonide or placebo will be inhaled once daily in the evening. The study consists of a baseline period (2 to 4 weeks) and a treatment period (12 weeks). The study provides further data on safety and tolerability of ciclesonide.
Conditions
- Asthma
Interventions
CiclesonideDrug
inhaled Ciclesonide
PlaceboDrug
Ciclesonide placebo-matching inhaler
SalbutamolDrug
Salbutamol inhalation powder
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Morning Peak Expiratory Flow (PEF)Time frame: Baseline and Week 12
Locations
122 sites in 9 countries. Site status is shown where the registry gives one.
Altana Pharma/Nycomed
Plovdiv, Bulgaria
Altana Pharma/Nycomed
Plovdiv, Bulgaria
Altana Pharma/Nycomed
Rousse, Bulgaria
Altana Pharma/Nycomed
Sofia, Bulgaria
Altana Pharma/Nycomed
Vama, Bulgaria
Altana Pharma/Nycomed
Dresden, Germany
Altana Pharma/Nycomed
Freising, Germany
Altana Pharma/Nycomed
Fulda, Germany
Altana Pharma/Nycomed
Homburg, Germany
Altana Pharma/Nycomed
Kassel, Germany
Altana Pharma/Nycomed
Leipzig, Germany
Altana Pharma/Nycomed
Mannheim, Germany
Altana Pharma/Nycomed
Marburg, Germany
Altana Pharma/Nycomed
München, Germany
Altana Pharma/Nycomed
Rosenheim, Germany
Altana Pharma/Nycomed
Schwäbisch Hall, Germany
Altana Pharma/Nycomed
Welzheim, Germany
Altana Pharma/Nycomed
Wesel, Germany
Altana Pharma/Nycomed
Budapest, Hungary
Altana Pharma/Nycomed
Budapest, Hungary
Altana Pharma/Nycomed
Debrecen, Hungary
Altana Pharma/Nycomed
Jászberény, Hungary
Altana Pharma/Nycomed
Kiskunhalas, Hungary
Altana Pharma/Nycomed
Miskolc, Hungary
Altana Pharma/Nycomed
Mosdós, Hungary
Altana Pharma/Nycomed
Mosonmagyaróvár, Hungary
Altana Pharma/Nycomed
Pécs, Hungary
Altana Pharma/Nycomed
Szeged, Hungary
Altana Pharma/Nycomed
Inowrocław, Poland
Altana Pharma/Nycomed
Lodz, Poland
Altana Pharma/Nycomed
Lodz, Poland
Altana Pharma/Nycomed
Lublin, Poland
Altana Pharma/Nycomed
Poznan, Poland
Altana Pharma/Nycomed
Torun, Poland
Altana Pharma/Nycomed
Warsaw, Poland
Altana Pharma/Nycomed
Warsaw, Poland
Altana Pharma/Nycomed
Zawadzkie, Poland
Altana Pharma/Nycomed
Brasov, Romania
Altana Pharma/Nycomed
Bucharest, Romania
Altana Pharma/Nycomed
Bucharest, Romania
Showing 40 of 122 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.